Arknights is the #1 Tower Defense Strategy RPG, and has set the golden standard for what a tactical Gacha game should be. It features a deep, rich, complex narrative (albeit a little drawn out at times,) some fantastic characters that are filled with personality (of every type,) great voice acting (if only the story were voice acted,) a lot of map diversity, character diversity in terms of abilities, and difficulty.

Players deploy a set number of units on to a grid-based battlefield, and attempt to stop waves of enemies from overrunning them. The concept of the game is very basic, but the more you play it, the more units you gain access to, the more enemy types you come into contact with, the more difficult it becomes and you begin to realize how complex the game truly is.

Developer

Hypergryph Studio Montagne

Publisher

Yostar

Status

Released.

China: May 2019

Globally: June 2020

Synopsis

The game is set in the dystopian, post-apocalyptic future setting of the planet Terra, where people exhibit kemonomimi features – characteristics of animals or mythological races. Natural disasters leave behind a valuable mineral, originium, which infects people with a progressive disease, oripathy, but also allows them to also use “Arts” (magic). Because oripathy is highly infectious and invariably fatal, the infected are shunned and persecuted. In response, some of them form the Reunion movement, a militant group waging war on the despotic governments of Terra.

The player takes the role of the masked and amnesiac “Doctor”, who commands a team of “operators” of Rhodes Island, a pharmaceutical, medical, and self-defense organization. As oripathy spreads, Rhodes Island searches for a cure while defending itself against Reunion and several of the governments of Terra.[7]

 

Arknights Going Into 2024

Arknights is a beautiful tactical tower defense RPG developed by Hypergryph and published Globally by Yostar. The game launched in China in 2019, with the rest of the world gaining access in 2020.Arknights has been met with repeated success and critical acclaim since...